^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    464 Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

    Published date:
    11/04/2020
    Excerpt:
    CONTRADICTING EVIDENCE: Pts received hyper-CVAD...followed by 4 cycles of blinatumomab...All relapses occurred in pts with established poor-risk features, including 2 pts with KMT2A rearrangement, 2 pts with TP53 mutation...
    Secondary therapy:
    CVAD
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    Published date:
    11/06/2019
    Excerpt:
    Twenty (74%) pts had CD20+ expression. Fifteen (56%) pts had high-risk features at baseline: 9 (33%) with TP53 mutation, 4 (15%) with Ph-like, 5 (19%) with Ho-Tr, 1 (4%) with t(4;11) and 1 (4%) with complex karyotype….The sequential combination of Hyper-CVAD and Blina in newly diagnosed B-ALL is safe and highly effective. This regimen produced CR in all pts and MRD eradication in 96% of pts. The preliminary survival outcomes are favorable.
    Secondary therapy:
    CVAD
    DOI:
    https://doi.org/10.1182/blood-2019-129657